Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Hydroxychloroquine protects against lupus flares during pregnancy, after delivery

07 Mar 2018

In women, the incidence of lupus flares appears to be high during pregnancy and within 3 months postpartum, a study reports. However, this flare risk can be mitigated by hydroxychloroquine (HCQ) treatment.

Researchers drew data from the 1987–2015 Hopkins Lupus Cohort and examined 1,349 women aged 14–45 years with >1 measurement of disease activity. There were 398 pregnancies reported in 304 women.

The main outcome was disease flare, which was defined as (1) change in Physician Global Assessment (PGA) ≥1 from previous visit and (2) change in Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) ≥4 from previous visit. Time-varying exposures were classified as pregnancy, postpartum or nonpregnant/nonpostpartum periods.

Results showed an increased rate of flare defined by PGA during pregnancy (hazard ratio [HR], 1.59; 95 percent CI, 1.27–1.96), but this effect was modified by HCQ use. The risk of flare during pregnancy relative to nonpregnant/nonpostpartum periods was increased by 1.26 times (0.88–1.69) among HCQ users and by 1.83 (1.34–2.45) among non-HCQ users.

The risk of flare was likewise elevated among non-HCQ users in the 3 months postpartum, but not among women taking HCQ after delivery.

Findings of the present study support prior data suggesting HCQ may prevent lupus flares during pregnancy and contribute evidence on the protective effect of the drug against postpartum flares, researchers said.

Taken together, the data provide reassurance to many women with lupus that they do not need to expect a lupus flare during or after pregnancy, particularly if they continue HCQ therapy, researchers added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.